BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 28596263)

  • 1. Integrating Immunotherapy Into the Management of Renal Cell Carcinoma.
    Zibelman M; Plimack ER
    J Natl Compr Canc Netw; 2017 Jun; 15(6):841-847. PubMed ID: 28596263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant Therapy Options in Renal Cell Carcinoma: Where Do We Stand?
    Martinez Chanza N; Tripathi A; Harshman LC
    Curr Treat Options Oncol; 2019 May; 20(5):44. PubMed ID: 31054006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Consensus paper: current state of first- and second-line therapy in advanced clear-cell renal cell carcinoma.
    Goebell PJ; Ivanyi P; Bedke J; Bergmann L; Berthold D; Boegemann M; Busch J; Doehn C; Krege S; Retz M; Amsberg GV; Grimm MO; Gruenwald V
    Future Oncol; 2020 Oct; 16(29):2307-2328. PubMed ID: 32964728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune checkpoint blockade as a novel immunotherapeutic strategy for renal cell carcinoma: a review of clinical trials.
    Godwin JL; Zibelman M; Plimack ER; Geynisman DM
    Discov Med; 2014 Dec; 18(101):341-50. PubMed ID: 25549705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma.
    Rini BI; McDermott DF; Hammers H; Bro W; Bukowski RM; Faba B; Faba J; Figlin RA; Hutson T; Jonasch E; Joseph RW; Leibovich BC; Olencki T; Pantuck AJ; Quinn DI; Seery V; Voss MH; Wood CG; Wood LS; Atkins MB
    J Immunother Cancer; 2016; 4():81. PubMed ID: 27891227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Game of thrones: immunotherapy versus molecular targeted therapy in renal cell cancer scenarios.
    Cetin B; Kosar A
    Int Urol Nephrol; 2019 Dec; 51(12):2107-2117. PubMed ID: 31468288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions.
    Lalani AA; McGregor BA; Albiges L; Choueiri TK; Motzer R; Powles T; Wood C; Bex A
    Eur Urol; 2019 Jan; 75(1):100-110. PubMed ID: 30327274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant therapy in renal cell carcinoma.
    Gul A; Rini BI
    Cancer; 2019 Sep; 125(17):2935-2944. PubMed ID: 31225907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma.
    Carlo MI; Voss MH; Motzer RJ
    Nat Rev Urol; 2016 Jul; 13(7):420-31. PubMed ID: 27324121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Changing Landscape of Management of Metastatic Renal Cell Carcinoma: Current Treatment Options and Future Directions.
    Salgia NJ; Dara Y; Bergerot P; Salgia M; Pal SK
    Curr Treat Options Oncol; 2019 Apr; 20(5):41. PubMed ID: 30937639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Checkpoint Blockade - a New Treatment Paradigm in Renal Cell Carcinoma.
    Grünwald V
    Oncol Res Treat; 2016; 39(6):353-8. PubMed ID: 27259695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer.
    Soria F; Beleni AI; D'Andrea D; Resch I; Gust KM; Gontero P; Shariat SF
    World J Urol; 2018 Nov; 36(11):1703-1709. PubMed ID: 29549485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging therapeutics in refractory renal cell carcinoma.
    Koshkin VS; Rini BI
    Expert Opin Pharmacother; 2016 Jun; 17(9):1225-32. PubMed ID: 27112171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant therapy for renal cell carcinoma.
    Haas NB; Uzzo R
    Curr Oncol Rep; 2008 May; 10(3):245-52. PubMed ID: 18765155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nivolumab in the treatment of advanced renal cell carcinoma.
    Arasaratnam M; Gurney H
    Future Oncol; 2018 Jul; 14(17):1679-1689. PubMed ID: 29460635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Checkpoint Inhibitors for the Treatment of Renal Cell Carcinoma.
    Ghatalia P; Zibelman M; Geynisman DM; Plimack ER
    Curr Treat Options Oncol; 2017 Jan; 18(1):7. PubMed ID: 28210995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy for renal cell carcinoma.
    Bleumer I; Oosterwijk E; De Mulder P; Mulders PF
    Eur Urol; 2003 Jul; 44(1):65-75. PubMed ID: 12814677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contemporary management of advanced renal cell carcinoma.
    Khanna A; Crane A; Yerram N; Sun D; Ericson K; Lundy SD; Abouassaly R
    Clin Adv Hematol Oncol; 2018 Jun; 16(6):438-446. PubMed ID: 30067615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overview of current and future systemic therapy for metastatic renal cell carcinoma.
    Osawa T; Takeuchi A; Kojima T; Shinohara N; Eto M; Nishiyama H
    Jpn J Clin Oncol; 2019 May; 49(5):395-403. PubMed ID: 30722031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma.
    de Velasco G; Bex A; Albiges L; Powles T; Rini BI; Motzer RJ; Heng DYC; Escudier B
    Eur Urol Oncol; 2019 Sep; 2(5):505-514. PubMed ID: 31377308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.